CATCH-HF: Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Hari Narayan
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Left ventricular ejection fraction (LVEF)
研究概览
简要总结
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.
详细描述
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.
Cardiac remodeling, function, and tissue characteristics will be examined using cardiac MRI in combination with other research assessments to assess the cardiotoxic effects of cancer therapy. Analyses will be performed in a cohort of adolescents and young adults with a history of childhood cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 13 Years 至 39 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •English and Spanish speaking male and female subjects, ages 13-39 years old
- •Diagnosis of cancer at age <22 years
- •Previously treated with anthracyline therapy for cancer, with diagnosis at least two years prior.
排除标准
- •Patients who have a contraindication to cardiac MRI, including the presence of non-MRI compatible metallic implants.
- •Medical, psychiatric, and/or social disorder that would prevent successful completion of planned study testing or would preclude the subject from undergoing the cardiac MRI without anesthesia.
- •Patients with a history of congenital heart disease (more significant than a history of patent foramen ovale or patent ductus arteriosus).
- •Pregnancy (at the time of enrollment).
结局指标
主要结局
Left ventricular ejection fraction (LVEF)
时间窗: 3 - 5 years
LVEF is an assessment of left ventricular global systolic function.
次要结局
未报告次要终点
研究者
Hari Narayan
Assoc Physician Dipl
University of California, San Diego